CEO Duffy Buys Big on OMADA’s Rally—Option Sales Show Confidence in Long‑Term Growth

Insider Activity at OMADA Health Inc. – What the Numbers Say

A Recent 10‑B5‑1 Buying Push

On August 7, 2026, CEO Sean P. Duffy executed two purchases of common stock under a pre‑adopted 10‑B5‑1 trading plan, buying 5,545 shares at $8.28 and 3,083 shares at $9.18. A third purchase followed on August 10 for 12,942 shares at $24.81, reflecting a sharp jump in the stock’s price from $8–$9 to roughly $25. The combined purchases brought Duffy’s holdings to 424,803 shares, just shy of the 425‑k mark he held earlier that month. These trades are fully compliant with the plan, but their timing and the price spike raise questions about his confidence in the company’s near‑term outlook.

Sell‑Side Activity and Option Exercise

The filing also reveals that Duffy sold 4,314 shares at $20.90 on June 26, 2026, and another 4,314 shares at $22.80 on August 7. He also sold 12,942 shares on August 10 for $24.81. These sales, coupled with the sale of 12,942 shares on August 7 for $20.90, suggest that he is periodically taking profits as the stock rallies. In addition, Duffy exercised and then immediately sold three stock‑option blocks (5,545; 3,083; 12,942 shares) under the same 10‑B5‑1 plan, converting options into cash at $0 cost to the company and then liquidating the shares. This pattern—exercise, sell, repeat—indicates a disciplined, plan‑driven approach rather than opportunistic market timing.

Implications for Investors

The dual nature of Duffy’s transactions—buying during a price surge and selling earlier at lower levels—signals a long‑term investment stance. His purchases at the $25 level align with the recent 18.98 % weekly gain and the stock’s 52‑week high of $26.92, suggesting he believes the current rally is sustainable. However, the sizable option sales indicate that he is comfortable realizing gains and may be hedging his exposure. For shareholders, this behavior is reassuring: the CEO is aligning his interests with the market and is not dumping shares at a discount.

What It Means for OMADA Health’s Future

OMADA Health’s market cap of $1.45 billion and a solid 19.51 % year‑to‑date gain underscore a company that is attracting institutional and retail attention. Duffy’s trades, particularly the recent large buy, can be interpreted as a vote of confidence in the company’s growth trajectory. The 10‑B5‑1 plan also provides predictability, reducing the risk of insider panic sales that could trigger volatility. Investors should watch for subsequent plan trades; a sustained buying pattern will likely support the stock’s momentum, while large sell orders could temper enthusiasm.

Profile of Sean P. Duffy

Since the beginning of the year, Duffy has traded in and out of OMADA shares roughly every week, alternating between purchases of 8–12 k shares and sales of 3–12 k shares. His average buy price has ranged from $5.82 to $24.81, while his average sell price has been $19.00–$24.81. He has also exercised and sold options on three separate occasions, converting a total of 33,470 shares from options to cash. Over the past twelve months, Duffy has net‑owned just over 850,000 shares, a significant stake that aligns his incentives with shareholder value. His disciplined use of a 10‑B5‑1 plan suggests a long‑term horizon and a willingness to participate in upside while managing downside risk.

Bottom Line

The current filing shows that CEO Duffy is both buying and selling in a structured, plan‑driven manner. His recent purchases at $25 reflect confidence in the stock’s trajectory, while his option sales demonstrate a willingness to lock in gains. For investors, this activity is a positive signal—one that aligns executive interests with shareholder returns—and indicates that OMADA Health is positioned for continued growth, provided it can sustain the momentum that has driven recent price gains.